A Phase III, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008004/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess the safety and efficacy of SPD503 (Guanfacine
hydrochloride) compared to placebo in the treatment of ADHD in children and adolescents aged
6-17
本研究旨在评估SPD503（盐酸胍法辛，Guanfacine hydrochloride）与安慰剂相比，用于治疗6至17岁儿童及青少年注意缺陷多动障碍（Attention Deficit Hyperactivity Disorder，ADHD）的安全性与有效性。
提供机构：
Vivli
创建时间：
2022-06-23
